🚀 Sign up Free for Company Insights & Valuation!
Sign up for free to get access to the best public company valuation and insights. Get started today and unlock the potential of your investments!
Sign up free
Ipsen
-4.64%
Pharma / Pharmaceuticals, Biotechnology
At a Glance | Core Facts | Company Due Diligence | Industry Due Diligence | Competitors | Stock Swings | News | Income | Balance | Cash Flow | Growth | Enterprise | Ratios | Metrics | Dividends | Risks | SWOT | Porter's Five Forces | PEST | Score Positive | Clusters | Reports | Web1. Regulatory Risks: Regulatory and legislative changes may affect the business operations of Ipsen, such as its pricing policies, access to markets, access to raw materials, or access to capital.
2. Market Risks: Ipsen’s success depends upon its ability to respond to shifts in consumer demand and preferences. Therefore, if Ipsen’s products become out of favor or are made obsolete due to technological innovations, its revenues would take a hit.
3. Competitive Risks: The biopharmaceutical industry is highly competitive and Ipsen faces competition from international and local companies, which can lead to lower profits or market share.
4. Financial Risks: Ipsen may face risks related to its investment portfolio. This can include interest rate fluctuations, foreign exchange risks, capital losses, and liquidity risks.
5. Operational Risks: IoT could lead to system failures or cyber-attacks. Furthermore, technological changes could disrupt the company’s operations, and supply chain disruptions could also lead to a loss of revenue.
Wait! There's more — sign up for free or log in